Royalty Pharma PLC (RPRX) To Go Ex-Dividend on August 14th

Royalty Pharma PLC (NASDAQ:RPRX) declared a quarterly dividend on Friday, July 17th. Investors of record on Friday, August 14th will be paid a dividend of 0.235 per share by the biopharmaceutical company on Thursday, September 10th. This represents a c) annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, August 14th.

Royalty Pharma has raised its dividend payment by an average of 0.2%annually over the last three years and has raised its dividend annually for the last 5 consecutive years. Royalty Pharma has a dividend payout ratio of 18.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Royalty Pharma to earn $5.53 per share next year, which means the company should continue to be able to cover its $0.94 annual dividend with an expected future payout ratio of 17.0%.

Royalty Pharma Trading Up 2.0%

Shares of RPRX stock traded up $1.16 during mid-day trading on Wednesday, hitting $58.95. 552,166 shares of the company’s stock were exchanged, compared to its average volume of 3,537,250. The stock has a market cap of $33.95 billion, a price-to-earnings ratio of 40.66, a PEG ratio of 1.35 and a beta of 0.43. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. Royalty Pharma has a fifty-two week low of $34.08 and a fifty-two week high of $60.44. The stock has a 50-day simple moving average of $56.60 and a two-hundred day simple moving average of $50.80.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.27 by $0.05. The company had revenue of $674.14 million during the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Equities analysts expect that Royalty Pharma will post 5.3 EPS for the current fiscal year.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.